

# VU Research Portal

## **Management of advanced non-small cell lung cancer: moving towards a more personalised approach**

Lind, J.S.W.

2012

### **document version**

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

### **citation for published version (APA)**

Lind, J. S. W. (2012). *Management of advanced non-small cell lung cancer: moving towards a more personalised approach.*

### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

### **E-mail address:**

[vuresearchportal.ub@vu.nl](mailto:vuresearchportal.ub@vu.nl)

## Contents

<b>Chapter 1:</b>	Introduction and outline of the thesis	9
-------------------	--	---

### *Part 1: Novel treatment approaches*

<b>Chapter 2:</b>	Time for reappraisal of extracranial treatment options? Synchronous brain metastases from non-small cell lung cancer.	25
<b>Chapter 3:</b>	Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small cell lung cancer.	43
<b>Chapter 4:</b>	Angiogenesis inhibitors in the treatment of NSCLC.	57
<b>Chapter 5:</b>	A multicenter, phase II study of erlotinib and sorafenib in chemotherapy-naïve patients with advanced non-small cell lung cancer.	79

### *Part 2: Optimising patient selection and treatment monitoring*

<b>Chapter 6:</b>	Fatal interstitial lung disease after erlotinib for non-small cell lung cancer. Case report.	99
<b>Chapter 7:</b>	Pulmonary toxicity following bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancer	107
<b>Chapter 8:</b>	Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity.	117
<b>Chapter 9:</b>	CD133+ circulating hematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.	123
<b>Chapter 10:</b>	Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method to monitor treatment?	141

<b>Chapter 11:</b> Osteoblastic bone lesions developing during treatment with erlotinib indicate major response in patients with non-small cell lung cancer. A Brief Report.	157
<b>Chapter 12:</b> Summary and discussion	165
<b>Chapter 13:</b> Nederlandse samenvatting	177
Dankwoord / Acknowledgements	191
CV	197
List of publications / Conference proceedings	201